Table 2.
Correlation between the frequency of potential nucleos(t)ide analog resistance mutation and clinical features
| No. of mutations | CH/HCC | HBeAg (positive/negative) | ALT (IU/L) | AST (IU/L) | HBV DNA | HBsAg |
| 0 | 27/25 | 29/23 | 108.51 ± 105.8 | 122.92 ± 106.8 | 6.50 ± 6.5 | 3.97 ± 3.8 |
| 1 | 18/16 | 21/13 | 101.61 ± 108.7 | 71.42 ± 126.1a | 6.91 ± 6.4 | 3.95 ± 3.8 |
| 2 | 9/19 | 15/13 | 81.10 ± 113.8 | 113.75 ± 113.0 | 6.65 ± 6.1 | 3.65 ± 3.9a |
| 3 | 4/7 | 3/8 | 211.45 ± 97.3 | 205.18 ± 104.8a | 6.84 ± 6.5 | 3.84 ± 3.8 |
| 4 | 1/4 | 2/3 | 56.60 ± 108.8 | 72.00 ± 114.8 | 5.85 ± 6.5 | 3.68 ± 3.8 |
| 5 | 0/1 | 1/0 | 24.23 | 39.05 | 7.49 | 2.83 |
| ≥ 1 (n = 79) | 32/47 | 42/37 | 105.81 ± 216.19 | 106.86 ± 131.51 | 5.11 ± 1.55 | 3.37 ± 0.77 |
| Total (n = 131) | 59/72 | 71/60 | 107.21 ± 191.16 | 113.2 ± 141.06 | 4.98 ± 1.51 | 3.43 ± 0.73 |
The significant values were shown in boldface and marked with asterisk (aP < 0.05). HbsAg: Hepatitis B virus surface antigen; HCC: Hepatocellular carcinoma.